The Foundation is pleased to designate a new Center of Excellence at the French National Institute for Health and Medical Research (INSERM) in Lyon, France. The Laboratory of Therapeutic Applications of Ultrasound (LabTAU) is located within a large medical and research community and conducts significant translational and clinical research with a multi-disciplinary, highly qualified, and complementary team of physicians and scientists. The Center has many years of experience in commercializing technology and creating strategic interfaces between engineering and medicine.
The concept of Open Science – or immediate access to papers, research data, and procedures – is changing how knowledge is shared. The Foundation is passionate about fostering collaboration among clinicians and researchers to drive progress, and Open Science is central to this mission. We are exploring ways to implement this approach in our research projects.
Foundation Chairman, Neal F. Kassell, MD, discussed the potential of focused ultrasound and his vision for creating the Foundation with Forbes. “[We want] to become the guiding light for the entire field….to accelerate the development and adoption of this amazing technology,” says Kassell. He goes on to discuss the hurdles involved in advancing a new therapy and how we plan to take on those challenges. READ THE ARTICLE >
The author, Josh Wolfe, covers innovative entrepreneurs and cutting-edge technologies.
Meredith Woo, PhD has been named the 13th president of Sweet Briar College. “Meredith is a valuable member of the Council and a close friend,” says Foundation Chairman Neal F. Kassell, MD. “We are happy to have her back in our neighborhood, and we are confident she will excel in this new role. We look forward to working more closely with her in the future.”
Three years ago, Shannon developed pain in her right leg and was diagnosed with an osteoid osteoma. The benign but painful bone tumor made it difficult to walk, play basketball, and even sleep through the night. A recent Miami Herald article tells how Shannon underwent focused ultrasound treatment, and now the high school senior is back on the court.
Patients with benign breast tumors may be eligible for a new focused ultrasound–based investigational treatment as part of a pivotal, multi-center clinical study. The trial, which uses Theraclion’s EchoPulse system, began last month at the University of Virginia (UVA) Medical Center and will include several sites worldwide. This study will build on results from a pilot study that also took place at UVA.
The Foundation’s latest Center of Excellence at the French National Institute for Health and Medical Research (INSERM) in Lyon, France is the Laboratory of Therapeutic Applications of Ultrasound (LabTAU). Co-led by Cyril Lafon, PhD, and Professor Michel Rivoire, MD, PhD, the Center has special expertise in commercializing technology and creating strategic interfaces between engineering and medicine. In addition, LabTAU trains young scientists and sponsors educational tracks that help form the next generation of researchers.
With the goal of slowing or reversing the negative neurological effects of multiple sclerosis, researchers at the University of Washington in Seattle recently completed an in vivo study using pulsed focused ultrasound to increase myelination of affected neurons in the brain. Could these findings lead to new treatment options for this disabling disease?
Focused ultrasound brain research is at the center of this month’s roundup. A new paper from Kullervo Hynynen’s group looks at blood-brain barrier restoration time; a new ultrasound technique for optogenetics is being developed at Columbia University; and our study with the University of Virginia compares focused ultrasound to the gamma knife for essential tremor thalamotomy.
Researchers at UCSF describe their series of 14 focused ultrasound treatments for desmoid tumors, noncancerous growths in the connective tissue. Those studied included three young patients with large posterior tumors. Technical data, lessons learned, and strategies for optimizing ablation size and safety - even when the desmoid is near a critical structure - are included.
Executives from NaviFUS in Taiwan visited the Foundation to share information on the status of their company and their plans to begin clinical trials. NaviFUS has designed and built a “neuronavigation guided” stand alone focused ultrasound system to temporarily and non-invasively open the blood-brain barrier and rapidly deliver drugs to a focal spot in the brain.